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INTRODUCTION
Dose-intensive treatment by induction chemotherapy and
post-remission therapy has brought a lot of progress in child-
hood acute myeloid leukemia (AML) (1), and allogeneic stem
cell transplantation (SCT) with a matched related donor (MRD)
is regarded as an effective post-remission therapy in pediatric
patients (2-4). But the majority of patients without an ap-
propriate related donor, received continuous chemotherapy.
Because relapse remains a major cause of failure and nearly a
half of patients are destined for relapse and a poor outcome
after complete remission, the identification of prognostic fac-
tors and risk-based post-remission therapy have been propos-
ed (5, 6). Although alternative donor transplants such as SCT
with a matched unrelated donor (MUD) are mainly applied
to restricted categories of cases (AML in second complete
remission [CR], third CR or early relapse), the high risk pati-
ents are regarded to have the advantage of receiving alterna-
tive donor transplants during the first remission (7). Recent-
ly, the FLT3 internal tandem duplication (FLT3/ITD) was
found to have profound prognostic effects, especially in pedi-
atric patients (8-15) and was proposed that a patient with
this mutation could be salvaged by allogeneic SCT, although
there has been some controversy (6, 16-18). Transcript level
of FLT3 was also proposed to have a prognostic significance
in adults (19, 20), but little is known for childhood AML. In
this study, transcript level of FLT3 was examined and ana-
lyzed with other prognostic factors in pediatric AML pati-
ents without very good prognostic factors such as t(15;17) and
inv(16), who achieved complete remission and we proposed
that high transcript level of FLT3 is associated with poor prog-
nosis in pediatric AML.
MATERIAL AND METHODS
Patients and treatment
Transcript level of FLT3 was analyzed with the initial bone
marrow sample in newly diagnosed pediatric patients (aged
≤18 yr) with AML who achieved the first complete remis-
sion. Patients with secondary AML or refroctory anemia with
excess blasts in transformation (RAEB-t) were included, but
patients with very good prognostic factors such as t(15;17)
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High Transcript Level of FLT3 Associated with High Risk of Relapse
in Pediatric Acute Myeloid Leukemia
Identification of prognostic factors and risk-based post-remission therapy was pro-
posed to improve the outcomes of acute myeloid leukemia (AML) and a mutation
of FLT3 has been reported to be a risk factor, especially for pediatric patients. Recent-
ly, FLT3 expression level was implicated to have prognostic significance in adults,
but little is known for childhood AML. To define the prognostic significance, tran-
script level of FLT3 was analyzed in 52 pediatric AML patients. The median copy
number of FLT3 was 4.6×10
3 (40-5.9×10
7 copies)/1.0×10
6 GAPDH copy, and the
relapse free survival of patients with high transcript level of FLT3 (>10
6 copy num-
ber) (0%) was significantly lower than that of the others (53.2%). High transcript level
of FLT3 was associated with a markedly high risk of relapse. The development of
new therapeutic scheme such as a frontline allogeneic stem cell transplantation or
administration of FLT3 inhibitor is needed to improve outcomes.
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entific purposes in this study was approved by the Institu-
tional Review Board of Seoul National University Hospital
(0507-507-153).
All patients received the same treatment scheme as previ-
ously reported after informed consent (9, 21). Briefly, patients
received N4-behenoyl-1-b-D-arabinofuranosyl-cytosine (BH-
AC), idarubicin, 6-thioguanine (6-TG), and intrathecal cyto-
sine arabinoside (Ara-C) as an induction therapy. Primary
refractory patients received a second cycle of induction thera-
py, excluding the 6-TG from the first regimen. Once in remis-
sion, patients with a MRD received SCT after two courses
of consolidation therapy. Patents without a donor received
autologous peripheral blood stem cell transplantation (APB-
SCT) with BCVAC (BCNU, etoposide, Ara-C, and cyclophos-
phamide) conditioning regimen after four courses of consol-
idation therapy. Recently, patient with appropriate alterna-
tive donor received unrelated SCT or cord blood transplan-
tation.
Analysis of FLT3 mutation and transcript level
Transcript level of FLT3 was analyzed with total RNA
extracted from bone marrow samples by using EASY-BLUE
total RNA extraction solution (InTron Inc., Seoul, Korea)
according to the manufacturer’s instruction. cDNA was syn-
thesized from each RNA (RNA measured by nano drop spect
auto calculation machine; error range±0.1-0.5%) by using
a RT premix kit (InTron Inc.). The transcript level of FLT3
was measured by using a real-time fluorescence detection
method on an ABI Prism 7000 sequence detection system
(Applied Biosystems, Foster City, CA, USA). The standard
curves for FLT3 and GAPDH mRNA were generated using
tenfold serial diluted FLT3 or GAPDH PCR products as tem-
plate, and the copy number of FLT3 and GAPDH transcript
was calculated from each standard curve. To compare the abso-
lute expression level of each sample, the FLT3 mRNA was
normalized using the expression of GAPDH gene, i.e. the
number of FLT3 copies was expressed as the equivalent copy
number per 106 copies of GAPDH. Each gene expression
level was analyzed in triplicate, and the mean was subjected
to analysis. The primer and probe sequences for RT-Q-PCR
of FLT3 were sense primer, 5′ -TTTCACAGGACTGGACA-
GAGATTT -3′ antisense primer, 5′ -GAGTCCGGGTGT-
ATCTGAACTTCT-3′ ; and TaqMan probe, FAM-5′ -CCAA-
ATTCCAGCATGCCTGGTTCAA-3′ -TAMRA. The house-
keeping gene, GAPDH, served as a control for cDNA qual-
ity and normalization and the primer and probe sequences for
real time quantitative PCR were sense primer, 5′ - TTTCA-
CAGGACTTGGACAGAGATTT-3′antisense primer, 5′ -
GAGTCCGGGTGTATCTGAACTTCT-3′ ; and TaqMan
probe, FAM-5′ -CAAGCTTCCCGTTCTCAGCC-3′ -TA-
MRA. FLT3 mutations were analyzed as previously reported
with genomic DNA isolated from bone marrow samples (9).
Statistics
Clinical and laboratory data were analyzed using standard
statistical methods in SPSS version 12.0. Fisher’s exact test
was used to compare categorical variables among subgroups.
Differences in means of continuous variables were analyzed
with the Mann-Whitney U test or Kruskal-Wallis test. Re-
lapse-free survival (RFS) was defined as the time from com-
plete remission to relapse, and for survival analysis, Kaplan-
Meier life tables were constructed and curves were compared
using the log-rank test. For multivariate analysis of prognos-
tic factors, a Cox proportional hazard regression model was
used.
RESULTS
Patient characteristics 
Fifty-two patients (33 males and 19 females) were analyzed
in this study. The median age at diagnosis was 8 yr 5 months
(4 months-17 yr 2 months). The clinical characteristics of the
52 patents are detailed in Table 1. All patients achieving CR
and thirty-six patients received post-remission therapy includ-
ing 16 APBSCT and 7 bone marrow transplantation (BMT)
with a MRD. One patient continued to receive chemothera-
py because of renal insufficiency compromising the transplant.
Twelve recently diagnosed patients with appropriate alterna-
tive donors received unrelated SCT or cord blood transplan-
tation.
Transcript level of FLT3
Transcript level of FLT3 was normalized with the 106 GA-
PDH copy number and the median level of 52 patients was
4.6×103 copies (40-5.9×107 copies). FAB subtype and risk
factors of AML such as an initial high WBC count (>100×
109/L), monosomy 7, more than one course for complete remis-
sion, secondary AML, MDS characteristics (RAEB-t), and
FLT3/ITD were not associated with the expression level of
FLT3 (Table 1).
Clinical characteristics of the patients with high transcript
level of FLT3
High transcript level of FLT3 (>106 copy number) was
found in 5 patient (9.6%). Among them 2 patients had the
FLT3/ITD mutation. High expression of FLT3 was not asso-
ciated with FLT3/ITD. Four patients experienced disease
recurrence before transplantation and one patient relapsed
after autologous peripheral blood transplantation. The clini-
cal data of these 5 patients are summarized in Table 2. A com-
parison of risk factors revealed that patients with high tran-
script level of FLT3 were not associated with any risk factors
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Clinical outcome and prognostic significance of transcript
level of FLT3
The overall survival (OS) (±standard error [SE]) and RFS
(±SE) of the 52 patients were 51.0±7.9% and 46.9±7.7%,
respectively. High transcript level of FLT3 (>106 copy num-
ber) was found to be a significant prognostic factor for RFS.
The RFS of patients with high expression level of FLT3 (0%)
was poorer than that of the other patients (53.2±8.0%) (Fig.
1), with statistical significance (P<0.001), and it was also a
significant prognostic factor for RFS by multivariate analy-
sis (P=0.042, RR=4.80 [1.06-21.73]) (Table 4). 
DISCUSSION
Currently, the remission rate of pediatric non-promyelo-
cytic AML is about 70-90%, but the survival rate has been
reported to be only 45-66% despite intensive post-remission
therapy (22). After the great success of treatment in pediatric
acute lymphoblastic leukemia (ALL) with risk based thera-
py, this kind of efforts are also introduced to AML (5, 6). But
treatment of AML is more intensive than ALL, and there is
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*WBC count of more than 100×10
9/L at diagnosis; 
� Presence of a clone
with at least five unrelated cytogenetic abnormalities.
Parameters Number
Transcript level of FLT3, 
median (range)
(copies/1.0×10
6 GAPDH copy)
Total 52 4,673  (40-59,283,120)
FAB classification
M1 5 5,025 (328-8,417,879)
M2 16 16,045 (122-59,283,120)
M4 12 3,548 (40-22,566,841)
M5 11 4,421 (81-2,882,400)
M6 1 3,018 (3,018-3,018)
M7 5 14,360 (1,209-475,389)
RAEB-t 2 348 (67-630)
Adverse prognostic factor
≥2 courses of induction 4 240,207 (1,425-8,417,879)
High initial WBC count* 6 7,409 (4,421-8,417,879)
Secondary AML 3 49,650 (122-22,566,841)
Monosomy 7 1 81 (81-81)
Complex karyotype
� 5 401,314 (14,360-59,283,120)
Favorable prognostic factor
t(8;21) 14 5,569 (178-3,326,274)
FLT3/ITD
Positive 7 8,964 (461-8,417,879)
Negative 45 4,421 (40-59,283,120)
FLT3/TK
Positive 2 461 (178-744)
Negative 50 4,934 (40-59,283,120)
Table 1. Patient characteristics and FLT3 transcription level
*Relapse before post-remission transplantation.
APBSCT, autologous peripheral blood stem cell transplantation; RFS, relapse free survival.
Patient 
number
FLT3 level
(×10
6 copies)
FLT3/
ITD
Age (yr)/
Sex
FAB subtype Karyotype
RFS
(months)
Post-remission
transplantation
7 1/M 2.89 - M5 t(1;3) 5 *
8 12/M 3.33 + M2 complex 4 *
9 9/M 59.28 - M2 complex 38 APBSCT
24 2/F 22.57 - M4 t(11;22) 4 *
42 12/M 8.42 + M1 46,XY 3 *
Table 2. Characteristics of patients with high FLT3 level (>10
6 copy number)
*WBC count of more than 100×10
9/L at diagnosis; 
� Presence of a clone
with at least five unrelated cytogenetic abnormalities.
Risk factors
FLT3 high
level (n=5)
FLT3 low level
(n=47)
P
≥2 courses of induction 1 3 0.34
High initial WBC count* 1 5 0.47
Secondary AML 1 2 0.27
Monosomy 7 0 1 1.00
Complex karyotype
� 2 3 0.07
RAEB-t 0 2 1.00
FLT3/ITD 2 5 0.13
Table 3. Relation between high FLT3 level and other risk factors
Fig. 1. The relapse free survival (RFS) of patients with high tran-
script level of FLT3 (0%) was lower than the RFS of the other pa-
tients (53.2±8.0%) (P<0.001).
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6not so much room for the stratification of treatment accord-
ing to the prognostic factors in AML. In the view of urgency
at diagnosis, it is somewhat hard to delay treatment in AML
until cytogenetic results are confirmed. Thus, many centers
start an induction regimen arranged beforehand. From this
point, the prognostic factors after CR have tremendous im-
portance.
BMT with matched sibling donor, introduction of inten-
sive induction chemotherapy and post-remission therapy have
done much to progress in the treatment of pediatric AML.
Recent development of SCT with the increase of unrelated
donor pool, the current proposal of risk based treatment in
AML is focused on finding patients who would have a bene-
fit from the allogeneic SCT. Some high risk factors have been
established in pediatric AML. An initial high WBC count
(>100×109/L), monosomy 7, more than one course for com-
plete remission, secondary AML, prior MDS, and extrame-
dullary leukemia (non CNS) are well known classical adverse
factors (23). Monosomy 7 as well as complex karyotype, mono-
somy 5, deletion 5q and abnormal 3q have been proposed
as adverse cytogenetic risk factors (5, 6, 24). 
FLT3 is a receptor tyrosine kinase involved in the survival
of hematopoietic stem cells and expressed in most acute leu-
kemia, including more than 90% cases of AML (2, 25, 26).
Mutations of FLT3 have been reported to be of prognostic
significance in many studies including our previous report
(8-15). But the role of allogeneic SCT in FLT3/ITD positive
AML was in debate (6, 16-18).
In our previous study, FLT3/ITD was a poor prognostic
factor and no patient survived (9), and FLT3/ITD also a poor
prognostic factor in present study but one patient with FLT3/
ITD was salvaged after cord blood transplantation.
To find another biological and clinical importance of FLT3,
overexpression of FLT3 has been studied and proposed to have
a prognostic significance in two adult studies (19, 20). But
the prognostic role of expression level of FLT3 was not known
for pediatric patients. 
In the present study, FLT3 transcript level was analyzed
in pediatric AML patients and high expression of FLT3 was
found to have prognostic significance. Our results simply
imply that patients with very high expression of FLT3 or
FLT3/ITD mutation have an extremely high risk of relapse,
and that this may justify the use of an alternative transplant
early after CR. 
FLT3 is a receptor tyrosine kinase and considered as a ther-
apeutic target in AML. Many phase I and II clinical studies
show a modest effect of small molecular compounds that
directly inhibit FLT3 and preliminary reports show the com-
bination of FLT3 inhibitors with chemotherapy was well-
tolerated with encouraging rates of clinical response (27, 28).
As with the promising results of incorporation of imatinib
into HSCT in Philadelphia positive leukemia, this kind of
agent would be incorporated into protocols for AML and
hopefully improve the treatment results in high-risk patients
with high expression of FLT3.
In conclusion, high transcript level of FLT3 was associat-
ed with a markedly high risk of relapse. The development
of new therapeutic scheme such as a frontline allogeneic stem
cell transplantation or administration of FLT3 inhibitor is
needed to improve outcomes.
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